ABCELLERA BIOLOGICS INC's ticker is ABCL and the CUSIP is 00288U106. A total of 170 filers reported holding ABCELLERA BIOLOGICS INC in Q2 2023. The put-call ratio across all filers is 0.65 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $283,473 | -69.7% | 95,768 | -53.6% | 0.00% | – |
| Q1 2024 | $935,114 | -72.8% | 206,427 | -65.7% | 0.00% | -100.0% |
| Q4 2023 | $3,433,086 | +187.8% | 601,241 | +131.9% | 0.00% | – |
| Q3 2023 | $1,192,762 | -56.1% | 259,296 | -38.3% | 0.00% | -100.0% |
| Q2 2023 | $2,714,989 | +2.5% | 420,277 | +19.6% | 0.00% | 0.0% |
| Q1 2023 | $2,649,149 | -43.7% | 351,346 | -24.4% | 0.00% | 0.0% |
| Q4 2022 | $4,709,193 | +118579.3% | 464,876 | +15.9% | 0.00% | 0.0% |
| Q3 2022 | $3,968 | +58.9% | 401,217 | +71.1% | 0.00% | 0.0% |
| Q2 2022 | $2,497 | -99.8% | 234,487 | +108.0% | 0.00% | – |
| Q1 2022 | $1,099,000 | -43.3% | 112,725 | -16.8% | 0.00% | – |
| Q4 2021 | $1,937,000 | +415.2% | 135,449 | +622.6% | 0.00% | – |
| Q3 2021 | $376,000 | -44.9% | 18,745 | -39.6% | 0.00% | – |
| Q2 2021 | $683,000 | -27.5% | 31,055 | +12.0% | 0.00% | – |
| Q1 2021 | $942,000 | – | 27,732 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Founders Fund VII Management, LLC | 3,773,530 | $28,452,416 | 91.13% |
| Founders Fund Growth Management, LLC | 407,017 | $3,068,908 | 14.23% |
| Gruss & Co., LLC | 167,500 | $1,262,950 | 7.99% |
| HARVARD MANAGEMENT CO INC | 4,105,095 | $30,952,416 | 3.25% |
| Belmont Capital, LLC | 510,000 | $3,845,400 | 3.18% |
| Prosight Management, LP | 753,528 | $5,681,601 | 2.69% |
| Intellectus Partners, LLC | 872,483 | $6,578,520 | 2.08% |
| Casdin Capital, LLC | 2,520,000 | $19,000,800 | 1.56% |
| GUARDIAN CAPITAL ADVISORS LP | 1,786,414 | $13,022,958 | 1.50% |
| Orbimed Advisors | 4,180,768 | $31,522,991 | 0.62% |